Our study demonstrated that several cancer-related mutations in the BEN domain of NACC1 and BANP disrupt DNA recognition, which may provide some clues for their relevance to human malignancy and may inspire us to identify new therapeutic strategies. This evidence concerns the gene NACC1 and cancer.